Quality and quantity: New strategies to improve immunotherapy of cancer

Trends in Molecular Medicine

Volumn 10, Issue 5, 2004, Pages 205-208

  Krueger, Christine ^a   Schneck, Jonathan P ^a   Oelke, Mathias ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOPTIVE IMMUNOTHERAPY; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; CANCER; DENDRITIC CELL; HLA MATCHING; HLA SYSTEM; HUMAN; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REVIEW; T LYMPHOCYTE;

EID: 2342533250     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2004.03.004     Document Type: Short Survey

References (32)

1. Walter E.A., et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 333:1995;1038-1044
2. + cytotoxic T lymphocyte responses in immunodeficient bone marrow transplant recipients by the adoptive transfer of T cell clones. Bone Marrow Transplant. 14:(Suppl 4):1994;S78-S84
3. Heslop H.E., et al. Donor T cells to treat EBV-associated lymphoma. N. Engl. J. Med. 331:1994;679-680
4. Brodie S.J., et al. HIV-specific cytotoxic T lymphocytes traffic to lymph nodes and localize at sites of HIV replication and cell death. J. Clin. Invest. 105:2000;1407-1417
5. Meidenbauer N., et al. Survival and tumor localization of adoptively transferred melan-A-specific T cells in melanoma patients. J. Immunol. 170:2003;2161-2169
6. + T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. U. S. A. 99:2002;16168-16173
7. Wilhelm M., et al. γδ T cells for immune therapy of patients with lymphoid malignancies. Blood. 102:2003;200-206
8. Khanna R., et al. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc. Natl. Acad. Sci. U. S. A. 96:1999;10391-10396
9. Roskrow M.A., et al. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. Blood. 91:1998;2925-2934
10. Sherritt M.A., et al. Reconstitution of the latent T-lymphocyte response to Epstein-Barr virus is coincident with long-term recovery from posttransplant lymphoma after adoptive immunotherapy. Transplantation. 75:2003;1556-1560
11. Khanna R., et al. Immunotherapeutic strategies for EBV-associated malignancies. Trends Mol. Med. 7:2001;270-276
12. Wong E.C., et al. Development of a clinical-scale method for generation of dendritic cells from PBMC for use in cancer immunotherapy. Cytotherapy. 3:2001;19-29
13. Lund P.K., et al. Isolation of monocytes from whole blood by density gradient centrifugation and counter-current elutriation followed by cryopreservation: six years' experience. Scand. J. Clin. Lab. Invest. 60:2000;357-365
14. + antigen-specific cytotoxic T lymphocytes after enrichment based on cytokine secretion: comparison with the MHC-tetramer technology. Scand. J. Immunol. 52:2000;544-549
15. + melan-A-specific cytotoxic T lymphocytes for adoptive transfer in tumor immunotherapy. Clin. Cancer Res. 6:2000;1997-2005
16. Ratta M., et al. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood. 100:2002;230-237
17. Ruffini P.A., Kwak L.W. Immunotherapy of multiple myeloma. Semin. Hematol. 38:2001;260-267
18. + T cells. Cancer Res. 62:2002;3459-3465
19. Bella S.D., et al. Altered maturation of peripheral blood dendritic cells in patients with breast cancer. Br. J. Cancer. 89:2003;1463-1472
20. Lee P.P., et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med. 5:1999;677-685
21. + T cells from HIV-1-infected donors after CD3/CD28 costimulation. J. Hematother. 7:1998;437-448
22. + T cells. Eur. J. Immunol. 27:1997;598-608
23. Oelke M., et al. Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells. Nat. Med. 9:2003;619-625
24. Zemon H. An artificial solution for adoptive immunotherapy. Trends Biotechnol. 21:2003;418-420
25. Snyder J.E., et al. Measuring the frequency of mouse and human cytotoxic T cells by the Lysispot assay: independent regulation of cytokine secretion and short-term killing. Nat. Med. 9:2003;231-236
26. + T cells specific to a single viral epitope. J. Immunol. 165:2000;6214-6220
27. Bachmann M.F., et al. Distinct kinetics of cytokine production and cytolysis in effector and memory T cells after viral infection. Eur. J. Immunol. 29:1999;291-299
28. Rubio V., et al. Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat. Med. 9:2003;1377-1382
29. Altman J.D., et al. Phenotypic analysis of antigen-specific T lymphocytes. Science. 274:1996;94-96
30. + T cells are activated in peripheral blood and accumulate in cerebrospinal fluid from HAM/TSP patients. Proc. Natl. Acad. Sci. U. S. A. 95:1998;7568-7573
31. Bercovici N., et al. New methods for assessing T-cell responses. Clin. Diagn. Lab. Immunol. 7:2000;859-864
32. Whiteside T.L. Monitoring of antigen-specific cytolytic T lymphocytes in cancer patients receiving immunotherapy. Clin. Diagn. Lab. Immunol. 7:2000;327-332